Equities

Electromed Inc

Electromed Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)26.44
  • Today's Change-0.40 / -1.49%
  • Shares traded144.50k
  • 1 Year change+157.95%
  • Beta0.2343
Data delayed at least 15 minutes, as of Nov 12 2024 23:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects the share price price of Electromed Inc to remain relatively unchanged over the next year.
High-1.7%26.00
Med-1.7%26.00
Low-1.7%26.00

Earnings history & estimates in USD

On Aug 27, 2024, Electromed Inc reported 4th quarter 2024 earnings of 0.20 per share. This result exceeded the 0.14 expectation of the one analyst covering the company and exceeded last year's 4th quarter results by 66.67%.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate+193.45%
Electromed Inc reported annual 2024 earnings of 0.58 per share on Aug 27, 2024.
Average growth rate+17.21%
More ▼

Revenue history & estimates in USD

Electromed, Inc. had 4th quarter 2024 revenues of 14.83m. This missed the 15.00m estimate of the one analyst following the company. This was 39.16% above the prior year's 4th quarter results.
Average growth rate+2.47%
Electromed, Inc. had revenues for the full year 2024 of 54.72m. This was 13.83% above the prior year's results.
Average growth rate+13.96%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.